In an effort to curb drug abuse, the sale of pseudophedrine products such as Claritin-D has been subjected to strict regulations. In turn, law-abiding allergy sufferers have been asked to provide identification upon every purchase. They may be denied the ability to purchase allergy treatment at their local pharmacy if their purchase exceeds the maximum amount allotted by the federal government.
As more allergy treatments move from prescription medications to over-the-counter, citizens in need of treatment are often left without it, because its distribution is dictated by store clerks instead of physicians.
Also, the quantity limits do nothing but benefit the manufacturers, who dictate the prices and keep them higher than what a citizen would pay under most healthcare prescription plans.